PI 2620
Alternative Names: [18F]PI-2620; PI-2620; Tau-PET tracer - AC ImmuneLatest Information Update: 24 May 2024
At a glance
- Originator AC Immune
- Developer AC Immune; Life Molecular Imaging; The Michael J. Fox Foundation for Parkinson's Research; University of Pennsylvania
- Class 3-ring heterocyclic compounds; Fluorinated hydrocarbons; Imaging agents; Pyridines; Pyrroles; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Alzheimer's disease; Dementia
- Phase II Parkinson's disease; Progressive supranuclear palsy
- Phase I Traumatic brain injuries
Most Recent Events
- 10 May 2024 Life Molecular Imaging terminates the phase I trial in Traumatic brain injuries in USA (IV) (NCT05337774)
- 05 Mar 2024 Life Molecular Imaging completes a phase-I clinical trial in Progressive supranuclear palsy (Diagnosis) in Germany (IV) (NCT05187546)
- 31 Dec 2023 AC Immune has patent protection for PI 2620